

1 **Increased Frequency of Acute Illness and Hospitalizations in Infants and Toddlers with**
2 **Congenital Adrenal Hyperplasia**

3 **Authors:** Teresa Tseng*, Amy Seagroves*, Christina M. Koppin, Madison Keenan, Elana
4 Putterman, Eugene Nguyen, Sanjay Chand, Mitchell E. Geffner, Todd P. Chang, Mimi S. Kim

5 *Authors contributed equally to the work

6 **Author details:** Division of Endocrinology, Diabetes, and Metabolism, Children’s Hospital Los
7 Angeles (A.S., C.M.K., M.K., E.P., M.E.G., M.S.K.)

8 Department of Pediatrics, Kaiser Permanente (T.T.)

9 Children’s Hospital Los Angeles (E.N., S.C.)

10 Division of Emergency Medicine, Children’s Hospital Los Angeles (T.C.)

11 Keck School of Medicine of University of Southern California (M.S.K., M.E.G., T.C.)

12 The Saban Research Institute (M.S.K., M.E.G., T.C.)

13 **Short Title:** Acute Illness in Infants and Toddlers with CAH

14 **Corresponding Author:** Mimi S. Kim

15 Children’s Hospital Los Angeles, 4650 Sunset Boulevard, Mailstop #61, Los Angeles, CA 90027

16 Phone: +1 323-361-1358 Fax: +1 323-361-1301 Email: mskim@chla.usc.edu

17 **Reprint requests** should be addressed to Mimi S. Kim

18 **Keywords:** congenital adrenal hyperplasia, 21-hydroxylase deficiency, adrenal insufficiency,
19 hospitalization, acute illness, stress-dose hydrocortisone

20 **Funding Sources:** K23HD084735 (NIH/NICHD) to M.S.K., Abell Foundation to M.E.G., and
21 the Gustavus and Louise Pfeiffer Research Foundation Award to A.S.

22 **Disclosure Summary:** M.E.G. receives consultant fees from Daiichi Sankyo, Ferring, Millendo
23 Therapeutics, Novo Nordisk, Nutrition & Growth Solutions, Pfizer, Sandoz, and Tolmar.

- 24 Mitchell E. Geffner also receives royalties from McGraw-Hill and UpToDate, and serves on data
25 safety monitoring boards for Ascendis, Millendo, and Tolmar.

26 **Abstract**

27 **Purpose:** Infants and toddlers with classical congenital adrenal hyperplasia (CAH) are at high
28 risk for adrenal crisis and associated sequelae. To better understand acute illness at this early age,
29 we determined the frequency and severity of acute illness and hospitalizations between 0-4 years
30 of age, both within CAH and compared to controls. We also evaluated the impact of pre-hospital
31 stress-dose hydrocortisone on Emergency Department (ED) visits and hospitalizations.

32 **Methods:** We performed a retrospective study of 40 CAH youth and 27 age-matched controls at
33 a tertiary center. Characteristics of acute illnesses during the first 4 years of life were recorded,
34 including fever, vomiting, diarrhea, ED visits, hospitalizations, abnormal electrolytes, and stress-
35 dose hydrocortisone usage.

36 **Results:** CAH youth had more frequent illnesses requiring stress-dosing when they were
37 younger than 2 years old [4.0 (1.0-6.0)] compared to when they were 2-4 years old [3.0 (1.0-4.0),
38 $P < 0.05$], with the most illnesses during their first year of life. As well, CAH infants and
39 toddlers had more hospitalizations younger than 2 years old compared to 2-4 years old (36 vs 2).
40 25% (3/12) of CAH youth with abnormal electrolytes in the ED did not receive any stress-dosing
41 (oral/IM) prior to the ED, and only 25% (3/12) had received intramuscular hydrocortisone at
42 home. CAH youth had more frequent ED visits (7.4 times as many) and hospitalizations (38 to 0)
43 compared to controls.

44 **Conclusions:** Very young children with classical CAH are at high risk for acute illness and
45 hospitalizations during their first 2 years of life, and do not receive adequate stress-dosing prior
46 to the ED despite appropriate education. Our findings underscore the need for earlier recognition
47 of acute illness in this vulnerable population and improved education regarding administration of
48 stress-dose hydrocortisone to prevent morbidity.

49 **Introduction**

50 Classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a
51 potentially life-threatening form of primary adrenal insufficiency that affects ~1:15,000 children,
52 and is characterized by stress hormone (cortisol and epinephrine) and aldosterone deficiencies,
53 along with androgen excess (1,2,3).

54 Infants and toddlers with CAH merit special attention, with increased all-cause mortality
55 between ages 1 to 4 years, and a high risk for hypoglycemia, seizures, hospitalization, permanent
56 cognitive impairment, and death caused by adrenal crisis during acute infectious illness (4,5,6,7).
57 Newborns diagnosed with salt-wasting CAH require rapid replacement of cortisol, aldosterone,
58 and salt to avoid catastrophic dehydration (6). In addition, newborns and infants with CAH
59 exhibit epinephrine deficiency (2), adding risk for illness, adrenal crisis, and Emergency
60 Department (ED) visits (8) at an age that inherently has an increased frequency of ED visits (9).
61 Age has been noted to be an important factor in the longitudinal study of illness in CAH patients,
62 with more illness events and stress-dosing noted to occur during childhood, and young age acting
63 as a robust predictor of stress-dosing during this period of life (8). However, more needs to be
64 understood about acute illness events and their pre-hospital treatment in infants and toddlers with
65 classical CAH.

66 The main objective of this study was to characterize the frequency and severity of acute
67 illnesses and hospitalizations in children with classical CAH during their infant and toddler
68 years. We evaluated age, frequency of stress-dose illnesses and associated symptoms (*e.g.*, fever
69 $\geq 100.4^{\circ}\text{F}$, vomiting, and/or diarrhea), pre-hospital management of acute illness including stress-
70 dose hydrocortisone, and severity of clinical presentation in the ED during the first 4 years of
71 life. We hypothesized that the frequency and severity of illness would negatively correlate with

72 age in CAH. We also compared CAH youth with age-matched controls, and hypothesized that
73 there would be more frequent illness, ED visits, and hospital admissions in the CAH group
74 compared to controls.

75 **Study Participants and Methods**

76 This study was a retrospective chart review approved by the Children's Hospital Los
77 Angeles Institutional Review Board. Parents gave their written informed consent.

78 *Study Participants*

79 Forty children with classical CAH were studied from 1 month to 4 years of age (Table 1).
80 CAH due to 21-hydroxylase deficiency was diagnosed biochemically based on a positive
81 newborn screening test (California Department of Health Services, starting in 2005), and/or an
82 elevated confirmatory serum 17-hydroxyprogesterone (17OHP) and androgen levels
83 (testosterone and androstenedione) measured by liquid chromatography-tandem mass
84 spectrometry LC-MS/MS (Esoterix, Calabasas Hills until 2009; Quest Nichols Diagnostics, San
85 Juan Capistrano after 2009). Thirty-five percent of subjects underwent genetic *CYP21A2*
86 analysis. There were 33 youth with the salt-wasting (SW) form and 7 with the simple-virilizing
87 (SV) form; of the total, 65% (25/40) were female. Doses of glucocorticoid, mineralocorticoid,
88 and sodium chloride were recorded for the children with CAH at both clinic and ED visits. CAH
89 youth were on higher hydrocortisone (HC) and fludrocortisone doses during their first 3-6
90 months of life compared to when they were older, and so we excluded 0-6 month-old dose data
91 from analyses of medication doses. Infants (with the exception of 3 SV) were treated with NaCl
92 doses of 11.5 (9.7-15.8) mEq/day largely in the first year of life.

93 CAH youth were age-matched to 27 controls, with no significant difference in sex
94 distribution between groups (Table 1). Controls had congenital hypothyroidism diagnosed by a

95 positive newborn screen (elevated TSH, California Department of Health Services), but were
96 otherwise healthy and euthyroid on replacement levothyroxine. The control group had a similar
97 frequency of laboratory testing and follow-up visits as the CAH group.

98 Data from medical records were collected, spanning 20 years, including information that
99 was recorded by a physician at clinic and ED visits at our institution. The number of acute
100 illnesses, along with specific symptoms accompanying each illness (*i.e.*, fever > 100.4° F,
101 vomiting, and diarrhea), were assessed. Hospital treatment per illness-event was assessed from
102 ED and inpatient admission records. In children with CAH, pre-hospital care was also assessed
103 per illness-event, including HC stress doses administered during illness (stress-dose illness) and
104 the route of administration [oral (PO) or intramuscular (IM) injection], as reported by caregivers.
105 Pre-hospital transport was assessed, including administration of IM HC by Emergency Medical
106 Services (EMS) personnel. ED serum electrolyte and glucose results were recorded, with
107 electrolyte derangements deemed as a combination of one or more of the following:
108 hyponatremia, hyperkalemia, and metabolic acidosis (low bicarbonate). Hypoglycemia was
109 defined as glucose < 60 mg/dL (3.3 mmol/L). Interventions performed in the ED, such as
110 administration of parenteral HC stress doses or intravenous fluids, were recorded from ED
111 records.

112 *Statistical Analyses*

113 SPSS software version 24 (SPSS Inc., Chicago, IL) was used for all statistical analyses.
114 Data were categorized into age groups of < 2 and ≥ 2 years old to evaluate modifying effects of
115 age on illness frequency, and were normalized by person-year. Wilcoxon-Signed Rank tests were
116 used for these comparisons. Chi-square tests and Spearman correlations were used for
117 comparison of acute illness characteristics within the CAH group. Chi-square tests (for

118 association) and Mann-Whitney U tests were used for comparisons between CAH and control
119 youth. All statistical assumptions were investigated before assessment and addressed when
120 necessary. The criterion for significance was $\alpha = 0.05$ in all analyses, while the Benjamini-
121 Hochberg procedure was used to control for false discovery rates. Results are shown as
122 frequencies and percentages, or median and interquartile range (IQR).

123 **Results**

124 **Illness Characteristics in CAH Youth**

125 CAH youth had more frequent stress-dose illnesses when they were younger than 2 years
126 old [4.0 (1.0-6.0)] compared to when they were 2-4 years old, per person-year [3.0 (1.0-4.0), $Z =$
127 -2.37 , $P < 0.05$; Figure 1]. In addition, CAH youth had more frequent stress-dose illnesses during
128 their first year of life [3.0 (1.0-4.0)] compared to their second year of life [1.0 (0-2.0), $Z = -3.03$,
129 $P < 0.01$].

130 CAH youth also had more frequent stress-dose illnesses involving vomiting when
131 younger than 2 years old [1.0 (0-2.0)] compared to when they were 2-4 years old [0 (0-1.0), $Z = -$
132 2.20 , $P < 0.05$; Figure 1]. However, there were no significant differences in frequency of stress-
133 dose illnesses involving fever or diarrhea when the two age groups were compared.

134 **Pre-Hospital Maintenance Medications and Stress-Dosing**

135 Maintenance medication doses were assessed over the first 4 years of life, excluding the
136 first 6 months of life when doses could typically be higher. CAH youth exhibited a higher
137 maintenance HC dose prior to 2 years old [15.1 (12.8-17.5) $\text{mg}/\text{m}^2/\text{day}$] compared to 2-4 years
138 old [13.5 (10.4-15.7) $\text{mg}/\text{m}^2/\text{day}$; $Z = -3.48$, $P < 0.001$]. There was no difference in
139 fludrocortisone dose prior to 2 years old and 2-4 years old.

140 Fludrocortisone dose correlated positively with frequency of overall stress-dose illness in

141 CAH youth prior to 2 years old ($R = 0.33$, $P < 0.05$), and with illnesses involving vomiting ($R =$
142 0.38 , $P < 0.05$) in particular. During this same age period, HC doses correlated with illnesses
143 involving diarrhea ($R = 0.38$, $P < 0.05$). When older (2-4 years old), HC doses also correlated
144 with total number of febrile illnesses in CAH youth ($R = 0.36$, $P < 0.05$), and trended towards
145 significance with abnormal electrolytes ($R = 0.29$, $P = 0.07$). There were no significant
146 correlations between HC or sodium chloride doses and frequency of stress-dose illness or with
147 illnesses involving vomiting.

148 **Stress-Dosing and ED Visits**

149 CAH youth had more frequent ED visits per person-year prior to 2 years old [1.5 (0.8-
150 3.5)] than when they were 2-4 years old, per person-year [0 (0-1.0), $Z = -4.17$, $P < 0.001$; Figure
151 2]. Illnesses requiring a pre-hospital HC stress dose, either PO and/or IM, directly correlated
152 with the number of ED visits ($R = 0.75$, $P < 0.01$). The highest newborn 17OHP level (*i.e.*,
153 newborn screen or initial pre-treatment confirmatory serum level; Table 1) was positively
154 associated with frequency of ED visits in CAH youth between the ages of 2-4 years ($R = 0.33$, P
155 < 0.05), but not when they were younger than 2 years old.

156 Of 149 ED visits, there were 101 visits where CAH youth were given stress-dose HC (80
157 parenteral and 21 PO) in the ED. In regard to the former, 78.8% (63/80) of parenteral stress
158 doses were administered in those who were younger than 2 years old and only 21.3% (17/80)
159 were preceded by a PO stress dose given at home. Only 21.3% (17/80) of parenteral stress doses
160 were administered when youth were between the ages of 2-4 years old.

161 Ten CAH youth received an IM HC injection at home and a subsequent intravenous (IV)
162 HC stress dose in the ED. Two youth received an IM HC injection at home, but did not receive a
163 parenteral stress dose when they were in the ED. Three youth received an IM HC injection at

164 home, but were not brought to the ED afterwards.

165 **ED Visits, Abnormal Electrolytes and Hypoglycemia, and Hospitalizations**

166 Electrolytes were checked in 74 of 149 ED encounters in CAH youth, with 29.7% (22/74)
167 being abnormal. There were five times the abnormal electrolyte events in CAH infants and
168 toddlers during their first 2 years of life (10 events) compared to when they were 2-4 years old
169 (two events). Eight events occurred during infancy, and two events between 1-2 years of age. All
170 22 encounters of abnormal electrolytes in these age groups resulted in parenteral HC stress-
171 dosing in the ED, of which 3 patients were subsequently admitted.

172 Only 25% (3/12) of infants and toddlers with abnormal electrolytes had received IM HC
173 prior to the ED, with two of the three injections given in youth older than 2 years old. Half (6/12)
174 of the cases had received a PO stress dose prior to the ED, but no IM HC, and 25% (3/12) had
175 not received any stress-dosing (PO or IM) prior to the ED.

176 In addition, there were four events of hypoglycemia in infants and toddlers with CAH.
177 Three of these events occurred during the first 2 years and one event occurred in a patient who
178 was 2-4 years old. All four patients were PO stress-dosed prior to their hypoglycemic event and
179 received parenteral HC at the ED. However, none of the patients had received IM HC prior to the
180 ED.

181 Overall, when CAH youth were younger than 2 years old, they had 18 times as many
182 hospitalizations compared to when they were 2-4 years old (36 vs 2). All 12 patients with
183 abnormal electrolytes in the ED were hospitalized. Four ED encounters involving normal
184 electrolytes also resulted in hospitalizations. One of these patients had received both PO and IM
185 HC stress doses at home, followed by an additional IV HC stress dose in the ED. CAH youth did
186 not have any hospitalizations requiring pediatric intensive care, nor were there any deaths.

187 **CAH vs Controls: Illness Characteristics**

188 CAH youth between the ages of 0-4 years old had significantly more frequent total
189 illnesses compared to controls [CAH 6.0 (3.2-9.0) vs controls 1.0 (0-4.0); $Z = -5.19$; $P < 0.001$],
190 per person-year. As well, CAH youth had more frequent illnesses involving fever [CAH 2.6 (1.1-
191 4.0) vs controls 0.5 (0-1.0); $Z = -4.85$; $P < 0.001$], vomiting [CAH 1.0 (0.8-2.8) vs controls 0 (0-
192 0.5); $Z = -4.70$; $P < 0.001$], and diarrhea [CAH 1.0 (0-2.0) vs controls 0 (0-1.0); $Z = -3.03$; $P <$
193 0.01].

194 **CAH vs Controls: ED Visits and Hospitalizations**

195 CAH youth between the ages of 0-4 years old had 7.4 times as many ED visits (149 visits
196 in 36 cases) compared to controls (20 visits in 10 cases), with an overall increased median
197 frequency of ED visits compared to controls [CAH 2.0 (1.0-4.8) vs controls 0 (0-1.0), $Z = -4.30$,
198 $P < 0.001$]. CAH youth had a total of 38 hospitalizations, with 36 occurring during their first 2
199 years of life and only two between the ages of 2-4 years old. The control infants and toddlers did
200 not have any hospitalizations.

201 **Discussion**

202 This study demonstrates that infants and toddlers with classical CAH have a significant
203 increase in frequency and severity of stress-dose illnesses during their first 2 years of life than
204 when older. CAH youth have more illnesses associated with vomiting, ED visits, and
205 hospitalizations when they are younger than 2 years old, compared to when they are 2-4 years
206 old, carrying significance for an age group known to have a high risk for morbidity and mortality
207 from adrenal crises (6,10). The adrenal stress-hormone deficiencies inherent to CAH (including
208 epinephrine deficiency in infancy) likely add to this heightened risk of decompensation with
209 acute illness generally seen in infants and toddlers (2,4,11). An even higher frequency of stress

210 dose-requiring illness in the CAH youth that we studied occurred during their first year of life,
211 further highlighting the risks at younger age in this condition.

212 We also found that infants and toddlers with CAH have more frequent ED visits and
213 hospitalizations than age-matched controls, along with higher rates of illness and symptoms of
214 fever, vomiting, and diarrhea. Morbidity associated with dehydration, hypoglycemia, and
215 subsequent adrenal crisis is particularly concerning in very young children (12,13,14,15), leading
216 us to consider the CAH infants and toddlers with abnormal electrolytes in the ED. The frequency
217 of abnormal electrolytes and hypoglycemia was significantly higher when children were younger
218 than 2 years old compared to between 2-4 years. This could also explain the correlation between
219 fludrocortisone dose and stress-dose illness, with patients on higher daily fludrocortisone doses
220 likely to have more severe salt-wasting during illness than patients on lower fludrocortisone
221 doses. Our finding supports prior reports of fludrocortisone dose as a predictive marker for
222 stress-dose requirement (8) and as a risk factor for hospitalizations in CAH (10).

223 The timely pre-hospital administration of stress-dose HC during acute illness seems
224 critical to the prevention of an adrenal crisis and its associated morbidity and mortality (16).
225 However, we found that only 25% (3/12) of CAH infants and toddlers with abnormal electrolytes
226 in the ED had appropriately received a stress-dose injection of HC at home. In fact, 25% of the
227 total cohort had not received any stress-dosing in the pre-hospital setting prior to the ED. It can
228 be challenging for parents to administer IM HC despite having significant knowledge (17),
229 perhaps due to technical difficulty with the kit or injection, lack of supplies, and/or psychological
230 stress in a high-acuity situation involving a young child. Education in a multidisciplinary clinic
231 could improve rates of IM HC administration during acute illness (18), although we still found
232 reluctance to administer IM HC by parents at our center who were taught stress-dosing at

233 diagnosis and had routine review at clinic visits by a clinician or nurse. We found that two
234 emergently ill toddlers (extreme lethargy in one and a seizure in the other) also did not receive an
235 injection from first responders, reflecting the lack of education regarding the emergency
236 hydrocortisone injection in the state of California. This suggests that standardizing the EMS
237 management of patients with adrenal insufficiency to include IM HC could minimize metabolic
238 derangements and prevent major morbidity related to adrenal crises in very young children with
239 CAH (19,20,21).

240 Despite most of our findings pointing towards an improvement in frequency and severity
241 of illness in CAH youth with age, we did note a correlation between the frequency of ED visits
242 and initial newborn 17OHP level when CAH youth were older toddlers (2-4 years old). Higher
243 daily hydrocortisone dose also correlated with more febrile illnesses at this age. This suggests
244 that CAH disease severity could continue to impact illness-related morbidity in older toddlers,
245 despite the expectation that frequency and severity of illness would improve at this age. Only
246 one-third of the sample had genetic testing, thus limiting analyses involving *CYP21A2* gene
247 mutations, but additional markers of CAH severity would be useful to study further.

248 Our study was limited by the retrospective nature of data collection, in terms of available
249 detail on illness-related measures such as the trajectory of symptoms, barriers to administration
250 of critical pre-hospital stress dosing, and time to hospital intervention. The number of acute
251 illness episodes may have been under-reported in controls, as illness history is not as critical a
252 component of medical history for a child who does not have adrenal insufficiency. Thus, a
253 prospective controlled study would help to better elucidate the connection between treatment
254 during illness and clinical outcome, and a larger sample size would also allow for more in-depth
255 analyses per year of life.

256 Our study highlights the heightened risk for acute illness, adrenal crisis, and related
257 morbidity that exists in youth with classical CAH when they are younger than 4 years old, and
258 even more so when they are under 2 years of age. Caregivers are rarely providing IM stress-
259 dosing with HC at home in young children with CAH, especially in those cases found to have
260 metabolic derangements in the ED, highlighting the need for better training of family caregivers
261 and EMS personnel, to improve outcomes in children with classical CAH.

262 **Acknowledgments**

263 We are very grateful to the patients and families who participated in the Natural History Study of
264 CAH from Infancy at our center. We thank CARES Foundation for support of the Children's
265 Hospital Los Angeles CAH Comprehensive Care Center, the Abell Foundation for ongoing
266 support of CAH research at our center, and the Gustavus and Louise Pfeiffer Research
267 Foundation Award for fellowship support. We also thank Heather Ross, Carol Winkelman, and
268 Norma Martinez for administrative support of this project.

269 **References**

- 270 1. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. *Lancet*. 2005;365(9477):2125-2136.
- 271 2. Kim MS, Ryabets-Lienhard A, Bali B, Lane CJ, Park AH, Hall S, Geffner ME. Decreased
272 adrenomedullary function in infants with classical congenital adrenal hyperplasia. *J Clin*
273 *Endocrinol Metab*. 2014;99(8):E1597-601.
- 274 3. Kim MS, Donohoue PD. Adrenal Disorders. In: Kappy MS, Allen DB, Geffner ME, eds.
275 *Pediatric Practice: Endocrinology*, 2nd Ed. New York: McGraw-Hill Education; 2013.
- 276 4. Keil MF, Bosmans C, Van Ryzin C, Merke DP. Hypoglycemia during acute illness in children
277 with classic congenital adrenal hyperplasia. *J Pediatr Nurs*. 2010;25(1):18-24.
- 278 5. Hinde FR, Johnston DI. Hypoglycaemia during illness in children with congenital adrenal
279 hyperplasia. *Br Med J* 1984;289(6458):1603-1604.
- 280 6. Swerdlow AJ, Higgins CD, Brook CG, Dunger DB, Hindmarsh PC, Price DA, Savage MO.
281 Mortality in patients with congenital adrenal hyperplasia: a cohort study. *J Pediatr*.
282 1998;133(4):516-520.
- 283 7. Rushworth RL, Falhammar H, Munns CF, Maguire AM, Torpy DJ. Hospital admission
284 patterns in children with CAH: Admission rates and adrenal crises decline with age. *Int J*
285 *Endocrinol*. 2016;2016:1-7.
- 286 8. El-Maouche D, Hargreaves CJ, Sinaii N, Mallappa A, Veeraraghavan P, Merke DP.
287 Longitudinal assessment of illnesses, stress dosing, and illness sequelae in patients with
288 congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 2018;103(6):2336-2345.
- 289 9. Wier LM (Truven Health Analytics), Hao Y (RAND), Owens P (AHRQ), Washington R
290 (AHRQ). Overview of Children in the Emergency Department, 2010. HCUP Statistical Brief
291 #157. June 2013. Agency for Healthcare Research and Quality, Rockville, MD.

- 292 <http://www.hcup-us.arhq.gov/reports/statbriefs/sb157.pdf>.
- 293 10. Yang M, White PC. Risk factors for hospitalization of children with congenital adrenal
294 hyperplasia. *Clin Endocrinol* 2017;86:669-673.
- 295 11. Mussa A, Porta F, Hoffmann GF, Sarafoglou K. Emergency assessment and management of
296 suspected inborn errors of metabolism and endocrine disorders. In: Sarafoglou K, Hoffmann GF,
297 Roth KS, eds. *Pediatric Endocrinology and Inborn Errors of Metabolism*, 2nd Ed. New York:
298 McGraw-Hill Education; 2017.
- 299 12. Tatro JB. Endogenous antipyretics. *Clin Infect Dis*. 2000;31 Suppl 5:S190-201.
- 300 13. Gennari FJ, Weise WJ. Acid-base disturbances in gastrointestinal disease. *Clin J Am Soc*
301 *Nephrol*. 2008;3(6):1861-1868.
- 302 14. Costanzo L. *Physiology*. 6th ed. Lippincott Williams and Wilkinson; 2003.
- 303 15. Tunkel A. Fever. In: Porter R, editor. *Merck Manual Professional Version* 2016.
- 304 16. Dorr HG, Wollmann HA, Hauffa BP, Woelfle J, German Society of Pediatric Endocrinology
305 and Diabetology. Mortality in children with classic congenital adrenal hyperplasia and 21-
306 hydroxylase deficiency (CAH) in Germany. *BMC Endocr Disord*. 2018;18(1):37.
- 307 17. Fleming LK, Rapp CG, Sloane R. Caregiver knowledge and self-confidence of stress dosing
308 of hydrocortisone in children with congenital adrenal hyperplasia. *J Pediatr Nurs*.
309 2011;26(6):e55-60.
- 310 18. Auchus RJ, Witchel SF, Leight KR, Aisenberg J, Azziz R, Bachega TA, Baker LA, Baratz
311 AB, Baskin LS, Berenbaum SA, Breault DT, Cerame BI, Conway GS, Eugster EA, Fracassa S,
312 Gearhart JP, Geffner ME, Harris KB, Hurwitz RS, Katz AL, Kalro BN, Lee PA, Alger Lin G,
313 Loechner KJ, Marshall I, Merke DP, Migeon CJ, Miller WL, Nenadovich TL, Oberfield SE, Pass
314 KA, Poppas DP, Lloyd-Puryear MA, Quigley CA, Riepe FG, Rink RC, Rivkees SA, Sandberg

315 DE, Schaeffer TL, Schlusser RN, Schneck FX, Seely EW, Snyder D, Speiser PW, Therrell BL,
316 Vanryzin C, Vogiatzi MG, Wajnrajch MP, White PC, Zuckerman AE. Guidelines for the
317 development of comprehensive care centers for congenital adrenal hyperplasia: Guidance from
318 the CARES Foundation Initiative. *Int J Pediatr Endocrinol*. 2010;2010:1-7.

319 19. CARES Foundation, Emergency Medical Care, Advocacy.
320 www.caresfoundation.org/emergency-medical-care/. 2012.


321 20. Emergency Medical Technician Scope of Practice. California Code of Regulations. Title 22,
322 Section 100063. Department of Health Services County of Los Angeles. 2015.

323 21. Office of Emergency Medical Services. Adult and Pediatric Adrenal Insufficiency. Statewide
324 Emergency Medical Services Protocols. Connecticut Department of Public Health. 2016.

325 **Table 1. Study Population**

Variable	N	Median (IQR)
CAH	40	-
Sex		
Female	26 (65.0%)	-
Male	14 (35.0%)	-
CAH Type		
Salt-wasting	33 (82.5%)	-
Simple-virilizing	7 (17.5%)	-
Initial 17OHP (ng/dL) [nmol/L]		
Newborn screen	33	9260.0 (3736.9-17612.5) [288.8 (135.1-537.6)]
Pre-treatment confirmatory serum	37	9875.0 (4931.5-25851.5) [295.7 (147.6-790.1)]
Highest (newborn or confirmatory)	40	14423 (6465.0-26923.3) [429.5 (189.2-822.0)]
CONTROL	27	-
Sex		
Female	20 (74.1%)	-
Male	7 (25.9%)	-

326



327

328 **Figure 1. Illness characteristics in youth with classical CAH when they are younger than 2**


329 **years old and 2-4 years old.** CAH youth had more frequent stress-dose illnesses when they were

330 younger than 2 years old [4.0 (1.0-6.0)] compared to when they were ≥ 2 years old, per person-

331 year [3.0 (1.0-4.0), $P < 0.05$]. CAH youth also had more frequent stress-dose illnesses involving

332 vomiting between the ages of 0-2 years old [1.0 (0-2.0)] compared to ≥ 2 years old, per person-

333 year [0 (0-1.0), $P < 0.05$].



334

335 **Figure 2. Emergency department visits in youth with classical CAH when they are younger**
336 **than 2 years old and 2-4 years old.** CAH youth had more frequent emergency department visits
337 during acute illness when they were younger than 2 years old [1.5 (0.8-3.5)] compared to when
338 they were 2-4 years old, per person-year [0 (0-1.0), $P < 0.001$].